Brief: Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
16/08/2023 11:15
Aug 16 (Reuters) - Eyenovia Inc EYEN.O :
* EYENOVIA ACQUIRES U.S. COMMERCIAL RIGHTS TO APP13007
(CLOBETASOL
PROPIONATE OPHTHALMIC NANOSUSPENSION, 0.05%) FROM FORMOSA
PHARMACEUTICALS
* EYENOVIA INC - PLANS TO EVALUATE NOVEL CLOBETASOL
FORMULATIONS
IN ITS PROPRIETARY OPTEJET DISPENSING PLATFORM AS A POTENTIAL
TREATMENT FOR DRY EYE
Source text for Eikon: ID:nGNX2kmW89
Further company coverage: EYEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Formosa Pharmaceuticals
See all newsBrief: Formosa Pharmaceuticals Announces Licensing Agreement With Rxilient
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%